Skip to main content

Cogent Biosciences

Cogent Biosciences Inc is an American clinical-stage biopharmaceutical company developing targeted precision therapies for genetically defined diseases. The company's lead candidate, bezuclastinib, is a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation driving systemic mastocytosis and advanced gastrointestinal stromal tumors. Main revenue drivers currently comprise investment capital financing, research grants, and potential milestone licensing payments as Phase III clinical trials advance. Cogent Biosciences targets hematologists, medical oncologists, clinical trial networks, and systemic mastocytosis patients across North America and Europe. The company holds an innovative position in precision kinase inhibitor development for rare genetic disorders. Headquartered in Waltham, Massachusetts, Cogent Biosciences Inc is listed on the Nasdaq Stock Market.

7 of the funds FundTelligence covers report a position in Cogent Biosciences.

Legal name
Cogent Biosciences Inc
Sector
Health Care
Country
United States
Funds holding it
7

Funds holding Cogent Biosciences

Loading...